( 22 US Oncology Affiliated Physicians Pa...)New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly,Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer,Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by,Paclitaxel,Health

HOUSTON, June 04, 2007 /PRNewswire/ -- A leading cancer researcher affiliated with the US Oncology Research Network presented findings from a randomized, multicenter phase III trial that compared the disease-free survival (DFS) obtained with two regimens of adjuvant therapy for patients with high-risk breast cancer.

The study results were given in an oral presentation by Dr. David Loesch of Central Indiana Cancer Centers, at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) held June 2-5, 2007 in Chicago. Dr. Loesch is the lead investigator and a member of US Oncology's breast cancer research committee.

The study, titled "A randomized, multicenter phase III trial comparing doxorubicin plus cyclophosphamide followed by paclitaxel or doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for high risk breast cancer" (abstract number 517) was conducted among women with local, operable, confirmed stage I-III adenocarcinoma, who had primary surgery, with no residual tumor.

The research found that Therapy Arm 2 (ATT) (doxorubicin 50 mg/m2 plus paclitaxel 200 mg/m2 repeated every three weeks for four cyclespaclitaxel 80 mg/m2 weekly x12) AT+WP can be considered equal to ACT as a standard treatment in the community. It has more peripheral neuropathy than ACT; but the neuropathy is reversible. In a repeat analysis of the triple negative subgroup, APWP was superior to ACT in overall survival (OS).

In addition, 22 physicians and researchers affiliated with US Oncology participated in oral and poster presentations, moderated panels and published studies at this year's ASCO conference in Chicago. The researchers presented findings on a variety of disease states including lung, gastrointestinal, genitourinary, gynecologic, breast and melanoma.

    -- Daniel Von Hoff, M.D.
'"/>




Page: 1 2 3 4 5 
Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment
of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin
Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement
of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy
of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than
Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show
Significant Improvement in Symptoms of Patients with Rheumatoid
Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized
Patients Surveyed are at Risk for VTE and Many do not Receive
Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox
(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10
Days for Reducing the Risk of Venous Thromboembolism (VTE) in
Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in
Patients with C. difficile Associated Diarrhea